Christopher Love

1. Quinoline or isoquinoline substituted P2X7 antagonists. WO 2009/132000.
2. Preparation of macrocyclic anilinopyridinotriazines as inhibitors of glycogen synthase kinase-3. WO 2007/003525.
3. Preparation of triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors. WO 2006/075023.
4. Preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors. WO 2005/012307 (EP granted 15.08.2007).
5. Preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors. WO 2005/012304 (EP granted 05.11.2008).
6. Preparation of heteroarylamines as glycogen synthase kinase 3-beta inhibitors. WO 2003/037891 (US granted 07.04.2009).
7. Preparation of pyrimidinylthiazoles as antiinflammatories. WO 2003/015776 (EP granted 10.05.2006).
8. Preparation of 2-amino-4,5-disubstituted thiazoles for treatment of inflammatory or autoimmune disease.WO 2003/015773.
9. Preparation of 2,4-disubstituted thiazoles for the prevention or the treatment of diseases mediated through cytokines. . WO 2001/064674 (EP granted 12.11.2008).
10. Preparation of 1,2,3,4-tetrahydro-benzofuro[3,2-c]pyridines as central alpha2 adrenoceptor antagonists.WO 1998/45297 (EP granted 30.06.2004).
11. Preparation of 2,4-diaminopyrimidines as dopamine D4 antagonists.
WO 1997/43279 (EP granted 21.04.2004).
12. Esters of 3-hydroxypiperidinemethanol derivatives, useful as gastroprokinetic agents. WO 1997/30031 (EP granted 31.07.2002).
13. Novel N-substituted 4-[[(4'-aminobenzoyl)oxy]methyl]piperidines having gastric prokinetic properties.